The P/E ratio measures how cheaply valued a company’s stock price is by dividing the current stock price to its earnings-per-share (EPS). It indicates the dollar amount an investor can expect to invest in a company to receive $1 of that company’s earnings. KemPharm P/E ratio is -1284.88. it has decreased in comparison to the same period last year. this metric is one of the most popular because it easily summarizes the status of the company. however, in order to make an informed decision, more metrics should be analysed. Let’s dive into KemPharm’s P/E ratio

**Contents**hide

## What is KemPharm P/E Ratio?

KemPharm’s P/E ratio is -1284.88, which represents a 8626.08 percent decrease from the same period last year. their 1-year average P / E ratio is -273.63 and their 5-year average is -71.08.

## What is KemPharm Net EPS?

KemPharm’s net earnings for the last quarter were -0.0$, which represents a 100.0% increase over the same period last year.

## Who are KemPharm Competitors?

Based on Jika.io AI model, Akebia Therapeutics, Ardelyx, Athira Pharma, Concert Pharmaceuticals, La Jolla Pharmaceutical, Opiant Pharmaceuticals, Rezolute, Syros Pharmaceuticals are considered to be KemPharm’s competitors because the companies operate within the same industry as KemPharm and they are targeting the same customer base. in addition, competitors typically share a similar market capitalization as KemPharm.

## Who is KemPharm’s Biggest competitor?

KemPharm’s biggest competitor is Akebia Therapeutics, based on the Jika.io AI model. it has a similar market capitalization to KemPharm in the industry, it dominates a similar share of the market as KemPharm, and it provides and markets very similar services.

## What industry is KemPharm in?

KemPharm is part of the biotechnology and healthcare industry.

## KemPharm vs Akebia Therapeutics

Market Cap: KemPharm’s Market Cap of 157659632 is higher than Akebia Therapeutics Market Cap of 84425176.

Average Volume: KemPharm’s Average Volume of 515981.0 is higher than Akebia Therapeutics Average Volume of 13.447M.

Beta: KemPharm’s Beta of 2.96 is higher than Akebia Therapeutics Beta of 1.55.

Revenue: KemPharm’s Revenue of 28.65M is higher than Akebia Therapeutics Revenue of 213.578M.

Net Income: KemPharm’s Net Income of -8.555M is higher than Akebia Therapeutics Net Income of -282.84M.

Gross Profit: KemPharm’s Gross Profit of 0.0 is lower than Akebia Therapeutics Gross Profit of 60.184M.

Ebitda: KemPharm’s Ebitda of -8.289M is higher than Akebia Therapeutics Ebitda of -244.87M.

P/E Ratio: KemPharm’s P/E Ratio of 13.47 is higher than Akebia Therapeutics P/E Ratio of -0.3.

P/S Ratio: KemPharm’s P/S Ratio of 7.71 is higher than Akebia Therapeutics P/S Ratio of 0.37.

P/B Ratio: KemPharm’s P/B Ratio of 1.3 is lower than Akebia Therapeutics P/B Ratio of 3.16.

P/FCF Ratio: KemPharm’s P/FCF Ratio of 16.77 is higher than Akebia Therapeutics P/FCF Ratio of -0.41.

ROE: KemPharm’s ROE of -0.0 is lower than Akebia Therapeutics ROE of -2.66.

ROA: KemPharm’s ROA of -0.0 is lower than Akebia Therapeutics ROA of -0.51.

Return On Capital Employed: KemPharm’s Return On Capital Employed of -0.01 is lower than Akebia Therapeutics Return On Capital Employed of -0.92.

Gross Profit Margin: KemPharm’s Gross Profit Margin of 0.82 is higher than Akebia Therapeutics Gross Profit Margin of 0.33.

Assets (Total): KemPharm’s Assets (Total) of 132.941M is lower than Akebia Therapeutics Assets (Total) of 525.55M.

Debt (Total): KemPharm’s Debt (Total) of 1.588M is lower than Akebia Therapeutics Debt (Total) of 136.048M.

Shareholders Equity: KemPharm’s Shareholders Equity of 127.118M is lower than Akebia Therapeutics Shareholders Equity of 76.456M.

## KemPharm vs Ardelyx

Market Cap: KemPharm’s Market Cap of 157659632 is higher than Ardelyx Market Cap of 90143016.

Average Volume: KemPharm’s Average Volume of 515981.0 is higher than Ardelyx Average Volume of 3.401M.

Beta: KemPharm’s Beta of 2.96 is higher than Ardelyx Beta of 1.85.

Revenue: KemPharm’s Revenue of 28.65M is higher than Ardelyx Revenue of 10.097M.

Net Income: KemPharm’s Net Income of -8.555M is higher than Ardelyx Net Income of -158.165M.

Gross Profit: KemPharm’s Gross Profit of 0.0 is lower than Ardelyx Gross Profit of 9.097M.

Ebitda: KemPharm’s Ebitda of -8.289M is higher than Ardelyx Ebitda of -152.218M.

P/E Ratio: KemPharm’s P/E Ratio of 13.47 is higher than Ardelyx P/E Ratio of -0.53.

P/S Ratio: KemPharm’s P/S Ratio of 7.71 is higher than Ardelyx P/S Ratio of 20.49.

P/B Ratio: KemPharm’s P/B Ratio of 1.3 is higher than Ardelyx P/B Ratio of 1.27.

P/FCF Ratio: KemPharm’s P/FCF Ratio of 16.77 is higher than Ardelyx P/FCF Ratio of -0.6.

ROE: KemPharm’s ROE of -0.0 is lower than Ardelyx ROE of -1.77.

ROA: KemPharm’s ROA of -0.0 is lower than Ardelyx ROA of -1.18.

Return On Capital Employed: KemPharm’s Return On Capital Employed of -0.01 is lower than Ardelyx Return On Capital Employed of -1.84.

Gross Profit Margin: KemPharm’s Gross Profit Margin of 0.82 is lower than Ardelyx Gross Profit Margin of 0.98.

Assets (Total): KemPharm’s Assets (Total) of 132.941M is lower than Ardelyx Assets (Total) of 149.913M.

Debt (Total): KemPharm’s Debt (Total) of 1.588M is lower than Ardelyx Debt (Total) of 45.504M.

Shareholders Equity: KemPharm’s Shareholders Equity of 127.118M is lower than Ardelyx Shareholders Equity of 82.617M.

## KemPharm vs Athira Pharma

Market Cap: KemPharm’s Market Cap of 157659632 is higher than Athira Pharma Market Cap of 114789800.

Average Volume: KemPharm’s Average Volume of 515981.0 is lower than Athira Pharma Average Volume of 819516.0.

Beta: KemPharm’s Beta of 2.96 is higher than Athira Pharma Beta of 0.0.

Revenue: KemPharm’s Revenue of 28.65M is higher than Athira Pharma Revenue of 0.0.

Net Income: KemPharm’s Net Income of -8.555M is higher than Athira Pharma Net Income of -54.853M.

Gross Profit: KemPharm’s Gross Profit of 0.0 is lower than Athira Pharma Gross Profit of 0.0.

Ebitda: KemPharm’s Ebitda of -8.289M is higher than Athira Pharma Ebitda of -63.543M.

P/E Ratio: KemPharm’s P/E Ratio of 13.47 is higher than Athira Pharma P/E Ratio of -1.71.

P/B Ratio: KemPharm’s P/B Ratio of 1.3 is higher than Athira Pharma P/B Ratio of 0.38.

P/FCF Ratio: KemPharm’s P/FCF Ratio of 16.77 is higher than Athira Pharma P/FCF Ratio of -2.11.

ROE: KemPharm’s ROE of -0.0 is lower than Athira Pharma ROE of -0.2.

ROA: KemPharm’s ROA of -0.0 is lower than Athira Pharma ROA of -0.21.

Return On Capital Employed: KemPharm’s Return On Capital Employed of -0.01 is lower than Athira Pharma Return On Capital Employed of -0.25.

Assets (Total): KemPharm’s Assets (Total) of 132.941M is lower than Athira Pharma Assets (Total) of 331.952M.

Debt (Total): KemPharm’s Debt (Total) of 1.588M is lower than Athira Pharma Debt (Total) of 1.92M.

Shareholders Equity: KemPharm’s Shareholders Equity of 127.118M is lower than Athira Pharma Shareholders Equity of 321.084M.

## KemPharm vs Concert Pharmaceuticals

Market Cap: KemPharm’s Market Cap of 157659632 is lower than Concert Pharmaceuticals Market Cap of 205788112.

Average Volume: KemPharm’s Average Volume of 515981.0 is lower than Concert Pharmaceuticals Average Volume of 831701.0.

Beta: KemPharm’s Beta of 2.96 is higher than Concert Pharmaceuticals Beta of 0.31.

Revenue: KemPharm’s Revenue of 28.65M is lower than Concert Pharmaceuticals Revenue of 32578.0.

Net Income: KemPharm’s Net Income of -8.555M is lower than Concert Pharmaceuticals Net Income of -80051.0.

Gross Profit: KemPharm’s Gross Profit of 0.0 is lower than Concert Pharmaceuticals Gross Profit of 0.0.

Ebitda: KemPharm’s Ebitda of -8.289M is lower than Concert Pharmaceuticals Ebitda of 1.399M.

P/E Ratio: KemPharm’s P/E Ratio of 13.47 is higher than Concert Pharmaceuticals P/E Ratio of -4.47.

P/S Ratio: KemPharm’s P/S Ratio of 7.71 is higher than Concert Pharmaceuticals P/S Ratio of 4.99.

P/B Ratio: KemPharm’s P/B Ratio of 1.3 is lower than Concert Pharmaceuticals P/B Ratio of 2.12.

P/FCF Ratio: KemPharm’s P/FCF Ratio of 16.77 is higher than Concert Pharmaceuticals P/FCF Ratio of -2.43.

ROE: KemPharm’s ROE of -0.0 is lower than Concert Pharmaceuticals ROE of -0.35.

ROA: KemPharm’s ROA of -0.0 is lower than Concert Pharmaceuticals ROA of -0.28.

Return On Capital Employed: KemPharm’s Return On Capital Employed of -0.01 is lower than Concert Pharmaceuticals Return On Capital Employed of -0.78.

Gross Profit Margin: KemPharm’s Gross Profit Margin of 0.82 is higher than Concert Pharmaceuticals Gross Profit Margin of 0.0.

Assets (Total): KemPharm’s Assets (Total) of 132.941M is lower than Concert Pharmaceuticals Assets (Total) of 165.316M.

Debt (Total): KemPharm’s Debt (Total) of 1.588M is higher than Concert Pharmaceuticals Debt (Total) of 1.155M.

Shareholders Equity: KemPharm’s Shareholders Equity of 127.118M is higher than Concert Pharmaceuticals Shareholders Equity of 112.225M.

## About KemPharm

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. the company uses its Ligand Activated Therapy technology to develop improved versions of FDA-approved drugs, as well as to develop versions of existing compounds that may have applications for new disease indications. its prodrug product candidate pipeline is focused on high-demand areas of attention deficit hyperactivity disorder, stimulant use disorder and CNS rare diseases, including idiopathic hypersomnia (IH). the company’s lead product candidate KP1077, which is in phase II clinical trials for the treatment of IH and narcolepsy, is based on its prodrug d-methylphenidate, known as serdexmethylphnidate. it is also developing KP879, a candidate for a prodrug for the treatment of stimulant use disorder, and is under Phase I clinical trial. in addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents aged six years and older, and for APADAZ, a combination product with benzhydrocodone, a prodrug for hydrocodone and acetaminophen. KemPharm, Inc. has a collaboration and license agreement with KVK-Tech, Inc. and Commave Therapeutics SA. the company was established in 2006 and is headquartered in Celebration, Florida.